A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

ABSTRACT: The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab monotherapy in participants with ovarian cancer and with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors.

DISEASE(S): Malignant Solid Tumors,Malignant Solid Tumor,Colorectal Neoplasms,Head And Neck Neoplasms,Ovarian Neoplasms,Pancreatic Neoplasms,Lung Neoplasms,Neoplasms

PROVIDER: 2067755 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR